

04-12-08

IRW

CASE ON/4-32700A



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 72727461745  
Express Mail Label Number

April 11, 2006  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
MANLEY ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/10724

FILED: 26 SEPTEMBER 2003

U.S. APPLICATION NO: 10/528,913 ✓

35 USC §371 DATE: 5 JANUARY 2006

FOR: NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE  
THEREOF

**MS: Amendment**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Lydia T. McNally  
Attorney for Applicants  
Reg. No. 36,214

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7898


Date: *April 11, 2006*

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32700A  
APPLICATION NO.  
10/528,913  
APPLICANT  
MANLEY ET AL.  
FILING DATE  
JANUARY 5, 2006

Group



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,215,989	06/01/93	Baldwin et al.			
	AB	5,521,184	05/28/96	Zimmermann			
	AC	5,516,775	05/14/96	Zimmermann et al.			
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AM	EP 0 233 461	08/26/87	Europe			<input type="checkbox"/>	<input type="checkbox"/>
	AN	EP 0 564 409	10/06/93	Europe [English equiv. is US 5,521,184]			<input type="checkbox"/>	<input type="checkbox"/>
	AO	EP 0 588 762	03/23/94	Europe [English equiv. is US 5,516,775]			<input type="checkbox"/>	<input type="checkbox"/>
	AP	GB 2 369 359	05/29/02	UK			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	WO 95/09847	04/13/95	WIPO			<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Buchdunger et al., "Selective Inhibition of the Platelet-Derived Growth Factor Signal Transduction Pathway by a Protein-Tyrosine Kinase Inhibitor of the 2-Phenylaminopyrimidine Class", <i>Proc Natl Acad Sci USA</i> , Vol. 92, No. 7, pp. 2558-2562 (1995).
	AS	Buchdunger et al., "Inhibition of the Abl Protein-Tyrosine Kinase <i>in Vitro</i> and <i>in Vivo</i> by a 2-Phenylaminopyrimidine Derivative", <i>Cancer Res</i> , Vol. 56, No. 1, pp. 100-104 (1996).
	AT	Carroll et al., "CGP 57148, A Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins", <i>Blood</i> , Vol. 90, No. 12, pp. 4947-4952 (1997).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Group

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	CA	WO 95/09852	04/13/95	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	CB	WO 01/47507	07/05/01	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	CC	WO 01/64200	09/07/01	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	CD	WO 02/22597	03/31/02	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	CE	WO 02/093164	11/21/02	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	CF						<input type="checkbox"/>	<input type="checkbox"/>
	CG						<input type="checkbox"/>	<input type="checkbox"/>
	CH						<input type="checkbox"/>	<input type="checkbox"/>
	CI						<input type="checkbox"/>	<input type="checkbox"/>
	CJ						<input type="checkbox"/>	<input type="checkbox"/>
	CK						<input type="checkbox"/>	<input type="checkbox"/>
	CL						<input type="checkbox"/>	<input type="checkbox"/>
	CM						<input type="checkbox"/>	<input type="checkbox"/>
	CN						<input type="checkbox"/>	<input type="checkbox"/>
	CO						<input type="checkbox"/>	<input type="checkbox"/>
	CP						<input type="checkbox"/>	<input type="checkbox"/>
	CQ						<input type="checkbox"/>	<input type="checkbox"/>
	CR						<input type="checkbox"/>	<input type="checkbox"/>
	CS						<input type="checkbox"/>	<input type="checkbox"/>
	CT						<input type="checkbox"/>	<input type="checkbox"/>
	CU						<input type="checkbox"/>	<input type="checkbox"/>
	CV						<input type="checkbox"/>	<input type="checkbox"/>
	CW						<input type="checkbox"/>	<input type="checkbox"/>
	CX						<input type="checkbox"/>	<input type="checkbox"/>
	CY						<input type="checkbox"/>	<input type="checkbox"/>
	CZ						<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32700A  
APPLICATION NO.  
10/528,913  
APPLICANT  
MANLEY ET AL.  
FILING DATE  
JANUARY 5, 2006

Group

EXAMINER  
INITIAL

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	Druker et al., "Effects of a Selective Inhibitor of the Abl Tyrosine Kinase on the Growth of Bcr-Abl Positive Cells", <i>Nat Med</i> , Vol. 2, No. 5, pp. 561-566 (1996).
	DB	Druker et al., "Selective Killing of Bcr-Abl Positive Cells with a Specific Inhibitor of the Abl Tyrosine Kinase", <i>Pezcoller Foundation Symposia, Cancer Genes</i> , pp. 255-267 (1996).
	DC	Zimmermann et al., "Phenylamino-Pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC)", <i>Arch Pharm Pharm Med Chem</i> , Vol. 329, No. 7, pp. 371-376 (1996).
	DD	Zimmermann et al., "Phenylamino-Pyrimidine (PAP) – Derivatives: A New Class of Potent and Highly Selective PDGF-Receptor Autophosphorylation Inhibitors", <i>Bioorg Med Chem Lett</i> , Vol. 6, No. 11, pp. 1221-1226 (1996).
	DE	Zimmermann et al., "Potent and Selective Inhibitors of the Abl-Kinase: Phenylamino-Pyrimidine (PAP) Derivatives", <i>Bioorg Med Chem Lett</i> , Vol. 7, No. 2, pp. 187-192 (1997).
	DF	
	DG	
	DH	
	DI	
	DJ	
	DK	
	DL	
	DM	
	DN	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.